Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, United States. The company describes itself as focused on achieving the most efficient development of products that address significant unmet needs in central nervous system (CNS) disorders and in rare diseases. Rather than marketing commercial medicines, Seelos is a development-stage enterprise whose value proposition rests on a pipeline of investigational product candidates, each designated with an "SLS" code, that it advances through clinical trials toward potential regulatory approval. The company's pipeline spans several distinct therapeutic approaches. Its lead program, SLS-002, is an intranasal formulation of racemic ketamine being studied for acute suicidal ideation and behavior (ASIB) in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). SLS-004 is a gene therapy candidate; SLS-005 is an intravenous trehalose program being evaluated in the HEALEY ALS Platform Trial (Regimen E) and in a study known as STRIDES-SCA; SLS-007 is a peptidic inhibitor; and SLS-009 is a protein-targeted autophagy program. This breadth reflects a strategy of pursuing multiple mechanisms across psychiatric, neurodegenerative, and rare-disease indications. Because Seelos is a publicly traded company, it maintains an investor relations function that publishes financial overviews, corporate governance materials, press releases, SEC filings, and stock information. Its board of directors sets governance standards and acts as fiduciary for shareholders, overseeing management of the business. The company also maintains a dedicated section for patients and caregivers, reflecting the patient populations affected by the conditions its candidates target. Seelos positions itself in the competitive and high-risk field of CNS drug development, where clinical outcomes are uncertain and timelines are long. Its communications emphasize unmet medical need — particularly in areas such as suicide risk in depression and neurodegenerative conditions like amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), which are addressed by its SLS-005 program. As a clinical-stage company without marketed products, its prospects depend on the success of its trials and its ability to fund continued development.

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, United States. Public records describe it as a company in New York, and its own corporate communications present it as an enterprise dedicated to the efficient development of products addressing significant unmet needs in central nervous system (CNS) disorders and rare diseases. The company is publicly traded, maintaining an investor relations program with published financial overviews, corporate governance documents, press releases, SEC filings, and stock information. Rather than commercializing approved medicines, Seelos has built its identity around a pipeline of investigational candidates identified by SLS codes. Its lead asset, SLS-002, is an intranasal formulation of racemic ketamine developed for acute suicidal ideation and behavior (ASIB) in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The company has reported Phase 2 activity for SLS-002, including a top-line data webcast, and has engaged in educational outreach such as a key opinion leader webinar on unmet medical needs in suicide and depression held in July 2023. Beyond SLS-002, the pipeline includes SLS-004, a gene therapy program; SLS-005, an intravenous trehalose candidate being evaluated in the HEALEY ALS Platform Trial (Regimen E) for amyotrophic lateral sclerosis and in the STRIDES-SCA study for spinocerebellar ataxia; SLS-007, a peptidic inhibitor; and SLS-009, a protein-targeted autophagy program. This portfolio reflects a strategy of pursuing multiple therapeutic mechanisms across psychiatric, neurodegenerative, and rare-disease indications. As a development-stage company without marketed products, Seelos operates in a capital-intensive and high-risk segment of the biotechnology industry. Its governance structure includes a board of directors that sets standards for employees, officers, and directors and acts as a fiduciary for shareholders. The company also maintains a section of its website for patients and caregivers, acknowledging the populations affected by the conditions its candidates target. Its long-term trajectory depends on clinical trial outcomes, regulatory progress, and access to financing.

• Seelos promoted a LifeSci Advisors KOL webinar on unmet medical needs in suicide and depression, scheduled for July 18, 2023.

• Seelos hosted a webcast presenting top-line Phase 2 data for SLS-002.

• SLS-005 (intravenous trehalose) was evaluated in the HEALEY ALS Platform Trial (Regimen E) and the STRIDES-SCA study.

Clinical-stage CNS and rare-disease drug developer focused on efficient development of therapies for significant unmet medical needs.

• SLS-002

  Intranasal racemic ketamine being studied for acute suicidal ideation and behavior (ASIB) in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD).

• SLS-004

  Gene therapy program.

• SLS-005

  Intravenous trehalose being evaluated in the HEALEY ALS Platform Trial (Regimen E) and the STRIDES-SCA study.

• SLS-007

  Peptidic inhibitor program.

• SLS-009

  Protein targeted autophagy program.

• 2021.01.26

  Reported2021.01.26

  Seelos Therapeutics prices public offering[4]Seelos Therapeutics公布公开发行定价investingnews.com

  Seelos Therapeutics announced pricing of an underwritten public offering of 15,243,903 shares of common stock at $2.05 per share. The offering was expected to close on or about January 28, 2021, subject to customary closing conditions.

• 2020.02.13

  Seelos Therapeutics closes $5 million public offering[5]Seelos Therapeutics完成500万美元公开发行newyork.citybuzz.co

  Seelos Therapeutics completed an underwritten public offering of 6,666,667 common shares at $0.75 per share, raising gross proceeds of $5 million. The company said it intended to use the net proceeds for general corporate purposes and to advance development of its product candidates.

Read more

1. 1Clinical Stage Therapeutics | Seelos Therapeutics, Inc.seelostherapeutics.com
2. 2Board Governance Policies by Seelos | Corporate Governanceseelostherapeutics.com
3. 3Seelos Therapeutics (United States) - Wikidatawikidata.org
4. 4Seelos Therapeutics公布公开发行定价investingnews.com
5. 5Seelos Therapeutics完成500万美元公开发行newyork.citybuzz.co